Compare Erasca Inc. Common Stock (ERAS) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Sherwin-Williams Company (The) Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.14B), while Sherwin-Williams Company (The) Common Stock trades at $325.43 (market cap $78.78B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 15.3× Erasca Inc. Common Stock's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ERAS | SHW | |
|---|---|---|
Market Cap | $5.14B | $78.78B |
Volume | 4,747,478 | 1,403,311 |
Sector | Health | Basic Materials |
52-Week High | $22.47 | $372.60 |
52-Week Low | $2.20 | $293.00 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $4.92B | $92.71B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
